On July 28, Innovita Biological Technology Co., Ltd. was listed on the SSE STAR Market with the stock code of 688253. Its issue price was CNY 26.06 per share. After the opening, the market value exceeded CNY 4.6 billion.

In 2020, the sales of the company's COVID-19 products was CNY 917 million, accounting for 88.42% of the main business income. In 2021, the company's COVID-19 products realized revenue of CNY 157 million.

In the first half of 2022, the company's operating income was CNY 249.794 million, a year-on-year increase of 15.06%, mainly because the company obtained the NMPA certificate for COVID-19 antigen test reagent which drove the performance growth. Therefore, the corresponding financial indicators such as operating profit, total profit, net profit attributable to shareholders of the parent company, and net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses have increased.

About Innovita

Innovita Biological Technology Co., Ltd. (together with its subsidiaries, collectively referred to as “INNOVITA”) is a biotechnology company specialized in R&D, manufacturing and sales of POCT in vitro diagnostic products, under which the subsidiaries including Innovita (Tangshan) Biological Technology Co., Ltd. have been established. 

Founded in 2006, Innovita Biological has been in possession of antigen antibody preparation, virus culture, colloidal gold, ELISA, fluorescent tomography, immunofluorescence and other technology platforms. Moreover, it has undertaken the national 863 project – National Special Research on Infectious Diseases and many public health projects. Furthermore, it also has over ten national innovation patents. INNOVITA has established Beijing R&D Center and Hebei Qian'an Manufacturing Base, and provided large-scale clean workshops. On this basis, it has built the production lines such as colloidal gold, ELISA, fluorescent tomography, PCR and immunofluorescence, and further passed CE and ISO13485 quality certification.